The impact of research and development and marketing costs on the profitability of pharmaceutical companies of Tehran Stock Exchange using panel data 2001-2013
| Autor: | Enayatollah Homaie Rad, Parna Farahmand, Banafshe Felezi Nasiri, Mehdi Mojahedian, Azita Nabizadeh, Mehdi Toroski, Yahya Bayazidi |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Marketing
business.industry 030503 health policy & services Health Policy Investment (macroeconomics) Pharmaceutical marketing 03 medical and health sciences 0302 clinical medicine Stock exchange Value (economics) Profitability index 030212 general & internal medicine Business Asset (economics) 0305 other medical science Panel data Pharmaceutical industry |
| Zdroj: | International Journal of Pharmaceutical and Healthcare Marketing. 10:467-476 |
| ISSN: | 1750-6123 |
| DOI: | 10.1108/ijphm-06-2015-0029 |
| Popis: | Purpose The main aim of this study is to investigate the effects of marketing and costs and research and development (R&D) investments on profitability of pharmaceutical companies of Iran. Design/methodology/approach In this study, pharmaceutical companies that have been accepted in Tehran Stock Exchange until March 19, 2013 were investigated. Random-effect panel data estimator was used for this purpose. Findings The findings indicate that variables such as company size, capital-to-total asset ratio and debt-to-asset ratio have an effect on profitability. But, company life, advertising cost and R&D investment are ineffective on profitability. Originality/value Legal issues like not having patent law and pricing mechanism are reasons for the ineffective relationship between R&D and marketing costs and its effect on profitability of the Iran pharmaceutical industry. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|